Shopping Cart
- Remove All
- Your shopping cart is currently empty
Cendakimab (RPC4046) is a humanized monoclonal antibody targeting IL-13. It selectively targets the IL-13 receptor (IL13R-α1 and IL13R-α2), used in research on atopic dermatitis.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $163 | In Stock | |
5 mg | $463 | In Stock | |
10 mg | $742 | In Stock | |
25 mg | $1,120 | In Stock | |
50 mg | $1,490 | In Stock |
Description | Cendakimab (RPC4046) is a humanized monoclonal antibody targeting IL-13. It selectively targets the IL-13 receptor (IL13R-α1 and IL13R-α2), used in research on atopic dermatitis. |
Targets&IC50 | IL-13α2:631 pM, aglycosylated IL-13:17  pM, IL-13Rα1:352 pM, glycosylated IL-13:37  pM |
In vitro | Cendakimab is an IgG1k humanized monoclonal antibody that recognizes IL-13 and inhibits its binding to IL-13 receptor-specific subtypes (IL-13-Rα1 and IL-13-Rα2) with an IC50 of 352 pM and 631 pM, respectively, as determined by ELISA. [2] cendakimab inhibited glycosylated and non-glycosylated IL-13-induced STAT6 activity in a dose-dependent manner with IC50 of 37pM and 17pM, respectively. [1] |
In vivo | In a mouse model of asthma, Cendakimab dose-dependent inhibited AHR (maximum inhibition 70.5%) and IL-13-dependent gene expression, and maximal inhibition of Muc5ac and AMCase activity was 70.7% and 54.2%, respectively. [2] |
Alias | RPC4046, RPC 4046, CC93538, CC 93538, ABT-308, ABT308 |
Cas No. | 2151032-62-9 |
Storage | store at low temperature | store at -20°C | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.